A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
LAVAL, QC / ACCESSWIRE / April 3, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced the first public drug plan listings for PrUCERIS® (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1
Mankind enters pact to distribute AstraZeneca's anti-asthma drug Symbicort
Calliditas announces an seven year orphan drug exclusivity period for TARPEYO®
Takeda wins US approval for first oral drug for eosinophilic esophagitis
Enforcement Report - Week of February 7, 2024
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
FDA grants Calliditas full nod for kidney disease drug Tarpeyo